Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Center for iPS Cell Research and Application, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan; iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.
Mol Cell Neurosci. 2020 Sep;107:103524. doi: 10.1016/j.mcn.2020.103524. Epub 2020 Jul 3.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that primarily targets motor neurons. Motor neurons from ALS patients show cytoplasmic inclusions that are reflective of an altered RNA metabolism and protein degradation. Causal gene mutations are found in all cell types even though patient motor neurons are by far the most susceptible to the degeneration. Using induced pluripotent stem cell (iPSC) technology, researchers have generated motor neurons with the same genotype as the patient including sporadic ones. They have also generated other cell types associated with the disease such as astrocytes, microglia and oligodendrocytes. These cells provide not only new insights on the mechanisms of the disease from the early stage, but also a platform for drug screening that has led to several clinical trials. This review examines the knowledge gained from iPSC studies using patient cells on the gene mutations and cellular networks in ALS and relevant experimental therapies.
肌萎缩侧索硬化症(ALS)是一种主要针对运动神经元的神经退行性疾病。来自 ALS 患者的运动神经元显示细胞质包含物,反映了改变的 RNA 代谢和蛋白质降解。即使患者的运动神经元是最容易受到退化影响的,在所有细胞类型中也发现了因果基因突变。使用诱导多能干细胞(iPSC)技术,研究人员生成了与患者相同基因型的运动神经元,包括散发性的。他们还生成了与疾病相关的其他细胞类型,如星形胶质细胞、小胶质细胞和少突胶质细胞。这些细胞不仅为疾病的早期机制提供了新的见解,还为药物筛选提供了一个平台,从而导致了几项临床试验。本综述检查了使用患者细胞进行 iPSC 研究在 ALS 中的基因突变和细胞网络以及相关实验治疗方面所获得的知识。